Boston Therapeutics has presented positive results of its PAZ320 drug, designed for reducing post-meal elevation of blood glucose, from its Phase ll clinical trial.
Non-systemic chewable complex carbohydrate-based drug is a proprietary polysaccharide which blocks the action of carbohydrate-hydrolyzing enzymes that break down carbohydrates into glucose and release it into the bloodstream.
The trial, which had enrolled 24 patients with Type 2 diabetes between the ages of 18 and 75 with a body mass index (BMI) of 25-40 kg/m2 and with HbA1c of less than or equal to nine percent, was designed to assess the safety and efficacy of PAZ320.
The study reported 40% reduction of post-meal glucose in the blood with no severe hypoglycemia and gastrointestinal side effects were mild.
In addition, the study showed no serious adverse events from the data analysis of the open-label dose escalation crossover trial on Type 2 diabetic patients.
Dartmouth Medical Center department of medicine endocrinologist and study co-principal investigator Sushela Chaidarun said uncontrolled diabetes can lead to micro- and macro-vascular complications, tighter but safe glycemic control is imperative.
“Optimal post-meal glucose control is one of the most difficult goals to achieve as Type 2 diabetes progresses, and PAZ320 may be helpful in achieving this goal,” Chaidarun added.
